Barcelona, Spain and Marin, CA, September 23, 2026 (Globe Newswire) -- Anaconda Biomed has closed a $56 million financing round led by Omega Funds, with participation from new investor Spain’s Co-investment Fund (FOCO) and existing backers including Asabys, Ysios Capital and CDTI. The company will use the proceeds to advance its neurovascular device portfolio and complete the ongoing ATHENA pivotal IDE study evaluating its ANA Funnel Catheter in a randomized 327-patient tri

San Diego, CA, September 21, 2026 (Business Wire) -- Travere Therapeutics announced that Eric Dube, Ph.D., will step down as President and CEO in December after nearly eight years leading the company. Bradley L. Campbell, former President and CEO of Amicus Therapeutics, will succeed Dube effective December 1, 2026, and will also join Travere’s Board of Directors. Dube will remain with the company as an executive advisor through February 15, 2027, to support the leadership t

Alachua and Tampa, FL, September 10, 2026 (Axogen) -- Axogen has entered into a definitive agreement to acquire privately held medical device company BioCircuit Technologies for $200 million in cash. The acquisition adds NerveTape, the first FDA-approved sutureless peripheral nerve repair device, to Axogen’s portfolio and is expected to broaden its addressable market. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions, includ

Boston, MA, September 15, 2026 (PR Newswire) -- CereVasc has appointed Tony Kingsley as President and Chief Executive Officer, effective September 15, succeeding Dan Levangie, who will transition to Chairman of the Board. Kingsley brings extensive commercial leadership experience in neurology and healthcare and will oversee the company’s strategy and operations as it prepares for the commercial introduction of its eShunt System. Levangie will continue supporting CereVasc’s

South San Francisco, CA, September 17, 2026 (Globe Newswire) -- Electra Therapeutics has priced an upsized initial public offering of 23.3 million shares at $15 per share, generating approximately $350 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 3.5 million shares, potentially increasing the proceeds from the offering. Electra plans to use the capital to advance its clinical-stage pipeline, led by ipsoprub

Boston, MA, September 3, 2026 (PR Newswire) -- Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors. The company will use the funding to advance its lead selective MC4R agonist for rare genetic and hypothalamic obesity into a Phase 1 clinical trial expected to begin by the end of 2026. Proceeds will also support additional pipeline progra

Bronx, NY, August 31, 2026 (Business Wire) -- Oligomerix has appointed biopharmaceutical veteran Cara Cassino, M.D., as Interim President and CEO as the company transitions from discovery research into clinical-stage development. Cassino brings 25 years of drug development and commercialization experience across major pharmaceutical and biotechnology companies, including leadership roles at Pfizer, Boehringer Ingelheim and Forest Laboratories. She will lead the advancement

Shanghai, China and Boston, MA, September 3, 2026 (NeuShen Therapeutics) -- NeuShen Therapeutics has completed an oversubscribed Series B financing of more than $80 million to expand its central nervous system drug pipeline. The round included participation from B Capital, Legend Capital, Matrix Partners China, TruMed Investment, and existing investor Lilly Asia Ventures. The company plans to use the proceeds to advance its CNS programs and accelerate global clinical develo

San Mateo, CA, August 26, 2026 (PR Newswire) -- Vivace Therapeutics has appointed Craig Gibbs, Ph.D., as President and CEO, while Ellen Lubman joins as Chief Business and Strategy Officer and oncology veteran Tim Clackson joins the board. The leadership changes come as the company prepares to advance VT3989, its lead TEAD inhibitor, into the pivotal Phase 3 sTEADfast trial for patients with previously treated mesothelioma. The FDA has granted the study a Safe to Proceed des

Boston, MA, September 8, 2026 (MedTech Dive) -- Elucid has raised $55 million in Series D financing to commercialize its cardiovascular imaging technology and expand partnerships with medical device companies. The company plans to use the funding to scale its clinical decision platform, including Plaque-IQ, which creates 3D models from coronary CT scans to analyze arterial plaque, and its FFR-CT technology currently under FDA review. The financing brings Elucid’s total fund

Seattle and Cambridge, MA, August 12, 2026 (Yahoo Finance) -- InduPro has closed a $77 million Series B financing led by The Column Group to fund development of its cancer-focused therapeutic pipeline. The company has also dosed the first patient in a Phase 1 study of IDP-001, a bispecific antibody-drug conjugate being evaluated in advanced squamous non-small cell lung cancer and other solid tumors. The financing will support clinical development, early proof-of-concept wor

RedWood City, CA, August 17, 2026 (Yahoo Finance) -- Juvena Therapeutics has appointed Julie Anne Smith as chief executive officer to lead the company’s next stage of growth. Smith brings extensive experience in biotechnology leadership and drug development, including senior roles focused on advancing innovative therapeutic programs. Her appointment is expected to support Juvena’s efforts to advance its pipeline and expand the potential of its protein-based drug discovery p

Cambridge, MA, August 19, 2026 (Business Wire) -- Amylyx Pharmaceuticals has priced an upsized public offering expected to generate approximately $500 million in gross proceeds. The company plans to use the capital to support development of its clinical-stage programs and broader corporate activities. The financing significantly strengthens Amylyx’s balance sheet as it advances its pipeline toward upcoming clinical milestones. Read full article here.

San Francisco, CA, August 18, 2026 (Yahoo Finance) -- Longevica Therapeutics has appointed Dr. Prasun Mishra, a former Genentech, Roche, and NIH executive, as chief executive officer and a member of its board. Mishra will lead the company as it transitions from large-scale longevity research toward developing therapeutic candidates and preparing for IND-enabling studies. His appointment follows the completion of Longevica’s $13 million mammalian screening program, which eva

Irving, TX, August 25, 2026 (Reuters) -- McKesson has agreed to acquire Precision Medicine Group in a transaction valued at approximately $2.25 billion. Precision provides clinical research, laboratory testing, and commercialization services to pharmaceutical and biotechnology companies, complementing McKesson’s existing oncology and multispecialty operations. The acquisition is expected to strengthen McKesson’s clinical trial capabilities and broaden its higher-growth heal

Duluth, GA, August 12, 2026 (Yahoo Finance) -- Bridge Life Sciences has raised $110 million in new financing to support the advancement of its therapeutic pipeline. The company plans to use the capital to accelerate development programs and strengthen its research and clinical capabilities. The financing provides additional resources to support the company’s growth and progress toward future clinical milestones. Read full article here.

Menlo Park, CA, August 5, 2026 (PacBio) -- Pacific Biosciences of California has appointed Mark Van Oene as president and chief executive officer, effective August 17, 2026. Van Oene brings extensive experience in the life sciences and genomics industry and will lead the company as it focuses on expanding adoption of its sequencing technologies. The leadership change is expected to support PacBio’s commercial growth and continued development of its long-read sequencing plat

Irvine, CA, August 6, 2026 (Reuters) -- Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals in a transaction valued at up to $800 million. The deal gives Tarsus access to an investigational therapy targeting Stargardt disease, an inherited retinal disorder with no approved treatment. The acquisition broadens Tarsus’ ophthalmology pipeline and supports its strategy of developing therapies for underserved eye diseases. Read full article here.

Santa Cruz, CA, August 11, 2026 (Business Wire) -- Versa Vascular has appointed Bill Shields as chief executive officer, bringing an experienced medical technology executive to lead the company’s next stage of growth. Shields will focus on advancing the company’s vascular technology platform and expanding its commercial reach. His appointment is expected to support broader adoption of Versa Vascular’s solutions and strengthen the company’s position in the vascular device ma

Dublin, Ireland, August 10, 2026 (Yahoo Finance) -- Jazz Pharmaceuticals has agreed to acquire privately held Actio Biosciences in a transaction valued at up to $1.32 billion. The deal adds ABS-1230, an investigational therapy being developed for KCNT1-related epilepsy, a rare inherited disorder that can cause severe seizures and developmental complications in children. The acquisition expands Jazz’s neuroscience portfolio and strengthens its focus on developing treatments